Washington D.c., DC5 Active Studies

HIV AIDS Clinical Trials in Washington D.c., DC

Find 5 actively recruiting hiv aids clinical trials in Washington D.c., DC. Connect with local research sites and explore new treatment options.

5
Active Trials
4
Sponsors
4,877
Enrolling

Recruiting HIV AIDS Studies in Washington D.c.

RecruitingWashington D.c., DCNCT07044297

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HI...

4,390 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingWashington D.c., DCNCT06694805

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite bein...

332 participants
ViiV Healthcare
View Study Details
RecruitingWashington D.c., DCNCT06532656

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

The goal of this clinical study is to learn about the safety and tolerability of bictegravir/lenacapavir (BIC/LEN) and to learn how the study drug interacts with the body in virologically suppressed (...

75 participants
Gilead Sciences
View Study Details
RecruitingWashington D.c., DCNCT04648280

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

In the SHIELD study, the study sponsor seeks to assess safety, PK and antiviral activity for children and adolescents with dual or triple class resistance. It will also assess the acceptability and sw...

60 participants
PENTA Foundation
View Study Details
RecruitingWashington D.c., DCNCT05674656

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virolog...

20 participants
ViiV Healthcare
View Study Details

About HIV AIDS Clinical Trials in Washington D.c.

HIV (human immunodeficiency virus) attacks the immune system and, if untreated, can lead to AIDS (acquired immunodeficiency syndrome). Antiretroviral therapy (ART) can control the virus and prevent transmission. Research continues to pursue a functional cure, long-acting therapies, and preventive vaccines.

There are currently 5 hiv aids clinical trials recruiting participants in Washington D.c., DC. These studies are seeking a combined 4,877 participants. Research is being sponsored by Merck Sharp & Dohme LLC, ViiV Healthcare, Gilead Sciences and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

HIV AIDS Clinical Trials in Washington D.c. — FAQ

Are there hiv aids clinical trials in Washington D.c.?

Yes, there are 5 hiv aids clinical trials currently recruiting in Washington D.c., DC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Washington D.c.?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Washington D.c. research site will contact you about next steps.

Are clinical trials in Washington D.c. free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Washington D.c. studies also compensate for your time and travel.

What hiv aids treatments are being tested?

The 5 active trials in Washington D.c. are testing new therapies including novel drugs, biologics, and treatment approaches for hiv aids.

Data updated March 2, 2026 from ClinicalTrials.gov